-
V V S Narayana Reddy Karri
Department of Pharmaceutics, JSS College of Pharmacy, Ootacamund, JSS University, Mysore, India.
-
Gowthamarajan Kuppusamy
Department of Pharmaceutics, JSS College of Pharmacy, Ootacamund, JSS University, Mysore, India.
-
Shashank Mulukutla
Department of Pharmacology, JSS College of Pharmacy, Ootacamund, JSS University, Mysore, India.
-
Sumeet Sood
Scientific writing, Indegene lifesystems pvt ltd, Manyata tech park, Bengaluru, India.
-
Rajkumar Malayandi
Pharmacokinetic Research and Development, Sun Pharmaceutical Industries Ltd, Part Survey No. 27 C.S No.1050, Village Tandalja, Baroda, India.
Abstract
A diabetic foot ulcer (DFUs) is a consequence of Diabetes Mellitus (DM) and involves complex pathological processes. It is a major cause of deaths among diabetic patients as a result of amputations. Various treatment strategies have been developed for the treatment of DFUs; unfortunately no single treatment will fulfill the prerequisites necessary for treating DFUs due to its complexed, multifactorial pathophysiology and also the overall cost of these treatments are high. Excipients are the pharmaceutical agents which have diverse applications in the design of different dosage forms. Hence, an ideal dosage form, with active excipients in combination or as adjuvants, which meets these requirements would probably best suited for treating DFUs. This review discusses the etiopathogenesis of DFUs and also the possible use of excipients and additives on various pathological cases of DFUs in designing products intended for the treatment of DFUs.
Author Biographies
V V S Narayana Reddy Karri, Department of Pharmaceutics, JSS College of Pharmacy, Ootacamund, JSS University, Mysore, India.
Department of Pharmaceutics
Shashank Mulukutla, Department of Pharmacology, JSS College of Pharmacy, Ootacamund, JSS University, Mysore, India.
Department of Pharmacology
Sumeet Sood, Scientific writing, Indegene lifesystems pvt ltd, Manyata tech park, Bengaluru, India.
Scientific writing
Rajkumar Malayandi, Pharmacokinetic Research and Development, Sun Pharmaceutical Industries Ltd, Part Survey No. 27 C.S No.1050, Village Tandalja, Baroda, India.
Pharmacokinetic Research and Development
Keywords
Excipients; additives; diabetes; diabetic foot ulcer; diabetic wound; chronic wound.
Authors who publish with this journal agree to the following terms: Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
